Results

RDF/XMLNTriplesTurtleShow queryShare
SubjectPredicateObject
http://purl.uniprot.org/citations/28051885http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/28051885http://www.w3.org/2000/01/rdf-schema#comment"

Background

Interferon γ-induced protein 10 kDa (IP10/CXCL10) is a chemokine related to endocrine disorders; however, the serum concentrations of IP10 in women with polycystic ovary syndrome (PCOS) have not yet been reported. Therefore, we investigated whether IP10 is increased in PCOS patients and its potential clinical value in PCOS patients.

Methods

For this research, the serum IP10, glucose, insulin, high sensitivity C-reactive protein (hs-CRP), follicle-stimulating hormone (FSH), luteinizing hormone (LH) and total testosterone (TT) concentrations were measured in 60 women with PCOS and healthy controls.

Results

The median IP10 concentration was 45.60 pg/mL [interquartile range (IQR):29.75, 79.69], which was significantly higher than that of the body mass index (BMI)-matched controls (median: 36.46 pg/mL; IQR:28.98, 45.80). In the multivariate linear regression analysis, hs-CRP and the homeostasis model assessment of insulin resistance index (HOMA2-IR) were independent predictors of the IP10 values, while FSH was inversely associated with the IP10.No significant association was observed between the IP10 and BMI, glucose, LH and TT.

Conclusions

The serum IP10 concentrations increase in women with PCOS, moreover, IP10 appears to be correlated with the inflammatory and IR statuses of PCOS. IP10 may be a potential biomarker to estimate the disease activity of PCOS."xsd:string
http://purl.uniprot.org/citations/28051885http://purl.org/dc/terms/identifier"doi:10.1080/09513590.2016.1269740"xsd:string
http://purl.uniprot.org/citations/28051885http://purl.uniprot.org/core/author"Chen Y."xsd:string
http://purl.uniprot.org/citations/28051885http://purl.uniprot.org/core/author"Li Z."xsd:string
http://purl.uniprot.org/citations/28051885http://purl.uniprot.org/core/author"Li X."xsd:string
http://purl.uniprot.org/citations/28051885http://purl.uniprot.org/core/author"Liu G."xsd:string
http://purl.uniprot.org/citations/28051885http://purl.uniprot.org/core/author"Sun Y."xsd:string
http://purl.uniprot.org/citations/28051885http://purl.uniprot.org/core/author"Zhang Y."xsd:string
http://purl.uniprot.org/citations/28051885http://purl.uniprot.org/core/author"Deng H."xsd:string
http://purl.uniprot.org/citations/28051885http://purl.uniprot.org/core/author"Fu J."xsd:string
http://purl.uniprot.org/citations/28051885http://purl.uniprot.org/core/date"2017"xsd:gYear
http://purl.uniprot.org/citations/28051885http://purl.uniprot.org/core/name"Gynecol Endocrinol"xsd:string
http://purl.uniprot.org/citations/28051885http://purl.uniprot.org/core/pages"363-367"xsd:string
http://purl.uniprot.org/citations/28051885http://purl.uniprot.org/core/title"Elevated serum interferon gamma-inducible protein-10 in women with polycystic ovary syndrome."xsd:string
http://purl.uniprot.org/citations/28051885http://purl.uniprot.org/core/volume"33"xsd:string
http://purl.uniprot.org/citations/28051885http://www.w3.org/2004/02/skos/core#exactMatchhttp://purl.uniprot.org/pubmed/28051885
http://purl.uniprot.org/citations/28051885http://xmlns.com/foaf/0.1/primaryTopicOfhttps://pubmed.ncbi.nlm.nih.gov/28051885
http://purl.uniprot.org/uniprot/#_P02778-mappedCitation-28051885http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/28051885
http://purl.uniprot.org/uniprot/P02778http://purl.uniprot.org/core/mappedCitationhttp://purl.uniprot.org/citations/28051885